Myocardial ischemia increases intracellular sodium ([Na]i). Since PKC has been shown to phosphorylate and lower Na,K-ATPase activity, we postulated that PKC inhibition would increase Na,K-ATPase activity and reduce [Na]i during ischemia. To test this hypothesis, isolated rat hearts had 30 min of global ischemia with and without pre-treatment with the specific PKC inhibitor chelerythrine 1 μM (CHEL). Intracellular pH, PCr, ATP, and [Na]i (31P and 23Na NMR spectroscopy) as well as Na,K-ATPase and PKC activity (biochemical assay) were measured. CHEL hearts had lower infarct size when compared with control (creatine kinase release: 48 ± 5 vs. 705 ± 72 IU/gdw; p = .008), but not different acidosis (nadir pH: 6.16 ± .05 CHEL vs 6.09 ± .03 control) or ATP depletion. The rise in [Na]i during ischemia was reduced in CHEL hearts (peak [Na]i CHEL: 21.5 ± 1.2 mM, control: 32.5 ± 0.8 mM; p < .0001), while Na,K-ATPase activity was significantly increased (5.5 ± 0.5 vs 4.1 ± 0.4 mg ADP/hr/mg protein; p = .0001). CHEL significantly reduced PKC activity (membrane and cytosolic fractions) under baseline conditions. These data support the hypothesis that PKC inhibition can reduce [Na]i overload via an increase in Na,K-ATPase activity, thus limiting ischemic injury.
|Original language||English (US)|
|State||Published - 1997|
ASJC Scopus subject areas
- Agricultural and Biological Sciences (miscellaneous)
- Biochemistry, Genetics and Molecular Biology(all)
- Cell Biology